These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 2354440)

  • 21. Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans.
    Neugebauer G; Wittenbrink-Dix AM; Woelke-Seidl E; Kaufmann B; Ponton T; Dahmen W; Mosberg H; Nieder N; Besenfelder E
    Arzneimittelforschung; 1989 Oct; 39(10A):1336-9. PubMed ID: 2576358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
    Herben VM; Schoemaker nE; Rosing H; van Zomeren DM; ten Bokkel Huinink WW; Dubbelman R; Hearn S; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):59-64. PubMed ID: 12111113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
    Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
    Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The disposition and metabolic fate of 14C-cibenzoline in man.
    Massarella JW; Loh AC; Williams TH; Szuna AJ; Sandor D; Bressler R; Leinweber FJ
    Drug Metab Dispos; 1986; 14(1):59-64. PubMed ID: 2868867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology of homoharringtonine.
    Savaraj N; Lu K; Dimery I; Feun LG; Burgess M; Keating M; Loo TL
    Cancer Treat Rep; 1986 Dec; 70(12):1403-7. PubMed ID: 3791253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers.
    Teichert J; Hermann R; Ruus P; Preiss R
    J Clin Pharmacol; 2003 Nov; 43(11):1257-67. PubMed ID: 14551180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
    Foster BJ; Wiegand RA; LoRusso PM; Baker LH
    Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of sulofenur (LY186641) in gastric cancer.
    Kamthan A; Scarffe JH; Walling J; Hatty S; Peters B; Coleman R; Smyth JF
    Anticancer Drugs; 1992 Aug; 3(4):331-5. PubMed ID: 1421428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.
    Taylor CW; Alberts DS; Peng YM; McCloskey TM; Matzner M; Roe DJ; Plezia PM; Grindey GB; Hamilton M; Seitz D
    J Natl Cancer Inst; 1992 Dec; 84(23):1798-802. PubMed ID: 1433369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs.
    Ehlhardt WJ; Sullivan HR; Wood PG; Woodland JM; Hamilton M; Hamilton C; Cornpropst D; Grindey GB; Worzalla JF; Bewley JR
    J Pharm Sci; 1993 Jul; 82(7):683-8. PubMed ID: 8360840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the methemoglobinemia associated with sulofenur.
    Molthrop DC; Wheeler RH; Hall KM; Prchal JT
    Invest New Drugs; 1994; 12(2):99-102. PubMed ID: 7860238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration.
    Vermeulen NP; Rietveld CT; Breimer DD
    Br J Clin Pharmacol; 1983 Apr; 15(4):459-64. PubMed ID: 6849782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new anticancer agent (LY186641) interferes with creatinine assay.
    Bonnay MM; Recondo G; Gouyette AJ; Armand JP
    Cancer Chemother Pharmacol; 1989; 23(2):119-20. PubMed ID: 2910508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureas.
    Ehlhardt WJ; Woodland JM; Worzalla JF; Bewley JR; Grindey GB; Todd GC; Toth JE; Howbert JJ
    Chem Res Toxicol; 1992; 5(5):667-73. PubMed ID: 1446007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.
    Talbot DC; Smith IE; Nicolson MC; Powles TJ; Button D; Walling J
    Cancer Chemother Pharmacol; 1993; 31(5):419-22. PubMed ID: 8431978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of sulofenur in refractory pediatric malignant solid tumors.
    Pratt CB; Bowman LC; Marina N; Pappo A; Avery L; Luo X; Meyer WH
    Invest New Drugs; 1995; 13(1):63-6. PubMed ID: 7499110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans.
    Hande KR; Kuttesch J; Hamilton M; Satterlee W; Jackson L; Grindey G; Hainsworth JD
    Cancer Res; 1990 Jul; 50(13):3910-4. PubMed ID: 2354440
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.